DUR-928
Sponsors
Durect
Conditions
Primary Sclerosing CholangitisSARS-CoV-2
Phase 2
A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
TerminatedNCT03394781
Start: 2018-01-22End: 2019-01-31Updated: 2022-10-17
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
TerminatedNCT04447404
Start: 2020-09-21End: 2021-03-04Updated: 2022-08-05